Hepatocellular carcinoma (HCC) is an inflammation-induced malignant disease of the liver. Abundant expression of immune checkpoint proteins has been reported in HCCs, which contribute to immune cell dysfunction and HCC progression. Immune checkpoint inhibitors as monotherapy or combination therapy have been approved by Food and Drug Administration for advanced HCCs. However, the median survival has not significantly improved, suggesting the need for exploring additional mechanisms to increase efficacy. Metabolic reprogramming is one of the mechanisms by which checkpoint proteins promote tumor growth and immune cell dysfunction. This review provides an insight into the role of immune checkpoint proteins on metabolic reprogramming in tumor and immune cells. An in-depth understating of these could help in the development of more efficacious and long-term therapies for HCC.

肝细胞癌（HCC）是一种由炎症引起的肝脏恶性疾病。据报道，免疫检查点蛋白在 HCC 中大量表达，这会导致免疫细胞功能障碍和 HCC 进展。免疫检查点抑制剂作为单一疗法或联合疗法已被食品和药物管理局批准用于晚期 HCC。然而，中位生存期没有显着改善，表明需要探索其他机制来提高疗效。代谢重编程是检查点蛋白促进肿瘤生长和免疫细胞功能障碍的机制之一。这篇综述深入了解了免疫检查点蛋白在肿瘤和免疫细胞代谢重编程中的作用。